# First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT05817058** · PHASE1 · TERMINATED · sponsor: **Affimed GmbH** · enrollment: 30 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** AFM28

## Key facts

- **NCT ID:** NCT05817058
- **Lead sponsor:** Affimed GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-21
- **Primary completion:** 2024-11-28
- **Final completion:** 2025-06-13
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** As decided by sponsor
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817058, "First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05817058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*